New amide derivatives of Probenecid as selective inhibitors of carbonic anhydrase IX and XII: biological evaluation and molecular modelling studies.

Novel amide derivatives of Probenecid were synthesized and discovered to act as potent and selective inhibitors of the human carbonic anhydrase (hCA, EC 4.2.1.1) transmembrane isoforms hCA IX and XII. The proposed chemical transformation of the carboxylic acid into an amide group led to a complete loss of hCA I and II inhibition (Kis >10,000nM) and enhanced the inhibitory activity against hCA IX and XII, with respect to the parent compound (incorporating a COOH function). These promising biological results have been corroborated by molecular modelling studies within the active sites of the four studied human carbonic anhydrases, which enabled us to rationalize both the isoform selectivity and high activity against the tumor-associated isoforms hCA IX/XII.

Exploring new Probenecid-based carbonic anhydrase inhibitors: Synthesis, biological evaluation and docking studies.

Novel Probenecid-based amide derivatives, incorporating different natural amino acids, were synthesized and assayed to test their effect on the human carbonic anhydrase (hCA, EC 4.2.1.1) transmembrane isoforms hCA IX and XII over the ubiquitous isoforms hCA I and II. Most of them presented a complete loss of hCA II inhibition (K(i)s > 10,000 nM) and strong inhibitory activity against hCA IX and XII in the nanomolar range with respect to the parent compound. A residual activity against hCA I was observed for some of them. These biological results have been explained by docking studies within the active sites of the four studied human carbonic anhydrases (with or without the zinc-bound water) and helped us to better comprehend the rationale behind the design of tertiary sulfonamide compounds as potent but atypical inhibitors of specific isoforms of human carbonic anhydrase.

Design, synthesis & structure-activity relationships of a new class of antihuman enterovirus D68 & A71 agents.

AIM: No antiviral medications are currently approved to treat enterovirus (EV)-associated disease or prevent EV infection. METHODS: In this study, a series of probenecid derivatives were designed via a rational strategy and synthesized to obtain more potent anti-EV agents. RESULTS: Compounds 8 and 24 exhibited the most potent activity against EV D68 and A71, with half maximal effective concentration (EC50) values of 2.49/2.09 and 2.59/2.41 µM, respectively, and revealed a broad inhibition spectrum toward other EV strains, with high selectivity indices. Additionally, compounds 8 and 24 showed good stability in rat serum, with half-lives of 48.39 and 60.26 min, respectively. CONCLUSION: Compounds 8 and 24 are the promising candidates for the development of new agents against EV D68 and A71 viruses.

The inhibitor effect of probencid and structural analogues on organic anions and chloride permeabilities in ox erythrocytes.

Probenecid inhibits anion movements (organic anions and chloride) in ox erythrocytes. The I50 is 4. 10(-5) M. Structural analogues such as carinamide, p-carboxybenzene sulfonamide and p-carboxy N,N-diethyl benzene sulfonamide, which are drugs of the sulfonamide class, were also found to inhibit anion transport. These results reinforce the previously discussed view based on structural considerations, that sulfonamides act on the red cell membrane as competitors of anion transport. It is possible that probenecid and carinamide act in a similar way in the kidney.

Increased rate of disappearance of serum probenecid in barbital dependent rats.

Rats were made barbital dependent by administration of barbital in their drinking water. Subsequently, the rats were either not withdrawn (BN) or withdrawn from barbital for 24 h (BW-24). Before sacrifice, probenecid was administered to measure brain serotonin turnover. A statistically significant decrease in 5-hydroxyindoleacetic acid (5-HIAA) accumulation was observed in the cerebral cortex medulla pons and midbrain. Subsequentialy, serum levels of probenecid were also measured by gas chromatography to determine if chronic barbital consumption might affect circulating probenecid. By ninety minutes following probenecid administration, serum probenecid levels in BN and BW-24 rats were significantly lower than control while a probenecid metabolite was significantly increased. The significantly reduced accumulation of 5-HIAA in brain areas of BN and BW-24 rats is probably the result of the more rapid decline of probenecid rather than a true decrease in serotonin turnover.

Inhibition of the conjugation of PABA with glycine in vitro by sulfamoyl benzoic acids, sulfonamides, and penicillins and its relation to tubular secretion.

Elimination of drug molecules via tubular secretion is an important pharmacokinetic parameter especially for oral dosage forms where an extremely short half-life would prevent their application. We have studied the inhibition in vitro of the glycination of p-aminobenzoic acid (PABA) using rat liver microsomal preparations. The I50 values, the concentration of the inhibitor that leads to 50% inhibition of glycine conjugation of PABA as compared to the control, have been determined for sulfamoyl benzoic acids, sulfonamides, and penicillins. Statistically significant regression equations were derived explaining the observed variation in I50 values as a function of lipophilicity and steric bulk of the substituents for the combined set of sulfamoyl benzoic acids and sulfonamides (n = 33). For the penicillins studied, only steric effects seem to be important for the explanation of the I50 values. Finally, regression analysis and the use of neural networks allowed the classification of compounds by their in vitro I50 values as being tubular secreted or not. Therefore, it can be concluded that the inhibition in vitro of the glycine conjugation of PABA is a useful model for the estimation of tubular secretion and drug interaction potential of acidic drug molecules in this process in vivo.

[Stimulation of the renal excretion of p-aminohippuric acid by probenecid homologues (author's transl)]. / Stimulation der renalen PAH-Ausscheidung durch Probenecid-Homologe.

Probenecid and five of its homologues showed increased lipophilicity with increasing chain length of the substituents. Parallel to this, the toxicity increased about 30 times. All the probenecide homologues under study stimulated the excretion of p-aminohippuric acid (PAH) when applied repeatedly. If a threshold dose is exceeded, an increase of the pretreatment dose will not result in a further increase in PAH excretion. As compared to non-pretreated control animals, the highest possible increase in PAH excretion lies between 40 and 80% independently of the structure of the respective probenecide homologue. Due to their more favourable therapeutic range (LD50 divided by D40-50), the probenecide homologues with shorter chains are better suited to stimulate the excretion of PAH, though the extent of stimulation is the same with all the probenicide homologues under study.

[Inhibition of the renal excretion of PAH by probenecid homologs]. / Hemmung der renalen PAH-Ausscheidung durch Probenecid-Homologe.

The authors studied the effects of probenecid and five of its homologues on the renal excretion of p-amino-hippuric acid (PAH). All the compounds under study inhibited the excretion of PAH. Probenecid and its homologues were injected 15 min before the administration of PAH. With all the substances tested, the inhibition of the excretion of PAH was most marked during the first 30 min of the diuresis experiment. The extent of efficiency increases within the homologous series up to the diethyl compound; after that, the inhibitory effect decreases with the increase in chain length. In the dosage range under study, the probenecid homologues show linear dose-response relationships. With due regard to toxicity and efficiency, the authors conclude from the results obtained that the diethyl compound is the most potent substance; probenecid itself is less efficient, being twice as toxic.

On the mechanism of p-piperidyl and p-benzyl sulfamyl benzoic acids transport by renal tissue.

The uptake of cyclic analogues of probenecid by kidney cortical slices has been studied in detail, in order to obtain more information on the secretory system for these compounds. Both p-piperidyl sulfamyl benzoic acid and p-benzyl sulfamyl benzoic acid were accumulated against concentration gradient, by renal tissue under aerobic as well as anerobic conditions. PAH, phenol red and probenecid competitively inhibited the active accumulation of these compounds by kidney tissue. Aerobic uptake of probenecid analogues was stimulated by succinate and octanoate at low medium concentrations while inhibition of renal accumulation of these compounds occurred at higher concentrations. Both p-piperidyl and p-benzyl sulfamyl benzoic acids like probenecid strongly interact with kidney cortex homogenates. Binding of these cyclic analogues to various cellular constituents of homogenate was efficiently inhibited by probenecid. The binding affinity of probenecid and analogues for kidney tissue, phospholipid vesicles (liposomes) and human serum albumin increased in the order : p-piperidyl sulfamyl benzoic acid less than p-benzyl sulfamyl benzoic acid less than di-n-propyl sulfamyl benzoic acid (probenecid). By contrast to the view put forward by Beyer (1950 & 1954), the results presented in this paper established that probenecid analogues are the true substrates of renal organic anion transport system.

Urate excretion: drug interactions.

A derivative of probenecid, 2-nitroprobenecid, was studied in chimpanzees and Cebus monkeys. The uricosuria induced by the drug could be diminished by the infusion of p-aminohippurate (chimpanzee) or hippurate (monkey). Both hippurates inhibited the secretion of the drug and it is likely that the diminished response was the result of decreased access of 2-nitroprobenecid to its site of action. In contrast, pyrazinoate diminished the response to 2-nitroprobenecid without disturbing its renal disposition (both species). This action of pyrazinoate is attributed to its ability to inhibit the secretory flux of urate. The effect of pyrazinoate is diminished at high levels of 2-nitroprobenecid, i.e., it appears as if pyrazinoate causes a shift to the right of the concentration-response curve of 2-nitroprobenecid. A mathematical model is developed which seems to explain this apparent shift in the concentration-response curve. This model requires that the transepithelial fluxes for urate be very large. In the chimpanzee the action of salicylate resembles that of pyrazinoate but it is less prominent.

Renal excretion of ascorbic acid in the rat: a micropuncture study.

Ascorbate concentration was measured by high-performance liquid chromatography and amperometry in plasma, tubular fluid, and urine from rats infused with ascorbic acid to steady-state levels. At a low concentration of ascorbate in plasma (Pasc = 0.2 mM) reabsorption occurred along the proximal convoluted tubule (PCT). The fractional delivery (FD) of ascorbate [(TF/P)asc/(TF/P)polyfructosan] to the late proximal convoluted tubule was 0.64 +/- 0.04, and the fractional excretion of ascorbate (FEasc) was 0.56 +/- 0.01. At higher Pasc (0.9 mM) net secretion occurred in the PCT, while the FDasc was 1.5 +/- 0.2 to the early and 1.8 +/- 0.2 to the late PCT. At still higher Pasc the secretory and the reabsorptive transports were saturated and the FDasc and FEasc approached unity, indicating that reabsorptive as well as secretory transport occurs in the proximal tubule. In clearance experiments the reabsorptive transport and secretory transport were inhibited by 2-nitroprobenecid. The drug induced a fall of FEasc when infused at a low rate (0.9 mumol X kg body wt-1 . min-1), which was followed by an increase in FEasc when the rate of infusion of 2-nitroprobenecid was increased to 3 mumol . kg body wt-1 X min-1.

[The level of penicillin in the blood serum during treatment of gonococcal infection with various doses of bicillin-3 and its combination with etamid]. / Soderzhanie penitsillina v syvorotke krovi pri lechenii gonokokkovoi infektsii razlichnymi dozami bitsillina-3 i kombinatsiei ego s étamidom.

Bicillin-3 has been administered to patients with new gonorrheal urethritis in doses of 3,000,000 U, 2,400,000 U, and 2,400,000 U + ethamide. The latter combination has proved to be the most effective.

Preparative chromatography of furosemide 1-O-acyl-glucuronide from urine using micronized amberiite XAD-2 and its application to other 1-O-acyl-glucuronides.

Furosemide 1-O-acyl glucuronide (Fgnd) was extracted from the urine following oral administration of furosemide. The crude Fgnd was applied to micronized Amberlite XAD-2 column (2.5 cm i.d. x 90 cm length, 75-500 microns particle size). The purified Fgnd was identified by mass spectrometry and beta-glucuronidase treatment. This method was also applicable to the purification of glucuronide of tolmetin (nonsteroidal anti-inflammatory drug, NSAID), suggesting that it was applicable to the other NSAIDs, most of which were known to be metabolized to acyl-glucuronides.